Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
Why the study?
Do Angiotensin II receptor blockers (ARBs) reduce cardiovascular morbidity and mortality and improve tolerability compared to ACE inhibitors in patients with cardiovascular disease?
Population
Patients with cardiovascular disease or at risk for diabetes
Comparison
Angiotensin II receptor blockers (ARBs) vs Angiotensin-converting enzyme inhibitors (ACE-Is)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May favor ARBs over ACE inhibitors for tolerability in CVD; leaves open dedicated trials confirming diabetes prevention.
Structured PICO
Do Angiotensin II receptor blockers (ARBs) reduce cardiovascular morbidity and mortality and improve tolerability compared to ACE inhibitors in patients with cardiovascular disease?
P
Population
Patients with cardiovascular disease or at risk for diabetes
I
Intervention
Angiotensin II receptor blockers (ARBs)
C
Comparator
Angiotensin-converting enzyme inhibitors (ACE-Is)
O
Outcome
Cardiovascular morbidity and mortality
ARBs provide effective cardiovascular protection with better tolerability than ACE inhibitors and may help prevent diabetes.
Cite This Study
Nickenig et al. (2006) studied this question.